HPS Pharmacies wish to advise that Sanofi-Aventis and Alphapharm are experiencing a supply interruption for rifampicin capsules as follows:
| Product | ARTG | Expected return date |
| Rifadin® 150mg | 233442 | End-January 2026 |
| Rifadin® 300mg | 233443 | End-January 2026 |
| Rimycin® 150mg | 48230 | Late October 2025 |
| Rimycin® 300mg | 48231 | Mid-November 2025 |
Internationally registered alternatives of the 300mg capsules have been approved for supply under Section 19A of the Therapeutic Goods Act 1989. Please note that S19A products may have a longer lead time as they must be sourced internationally.
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact your pharmacist at HPS Pharmacies.
Subscribe Knowledge Centre Updates
Enter your details to receive Knowledge Centre updates